METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS

Abstract

In various aspects and embodiments provided are compositions and methods for a disease or disorder in a patient such as a disease or disorder that affects the brain in a patient and treating such patient.

What is claimed is: 
     
         1 . A method comprising identifying a patient diagnosed with nOH or in need of treatment for nOH and administering to said patient an α 1A -AR partial agonist, wherein the α1A-AR partial agonist is dabuzalgron. 
     
     
         2 . The method of  claim 1 , wherein said patient meets at least one or more of the following diagnostic criteria: (1) demonstrate a >20-30 mmHg drop in SBP within 5 minutes of standing; (2) demonstrate impaired autonomic reflexes as determined by absence of BP overshoot during phase IV of the Valsalva maneuver; (3) experience dizziness, light-headedness, or fainting when standing; and (4) have an absence of other identifiable causes of autonomic neuropathy. 
     
     
         3 . The method of  claim 1 , wherein peripheral vascular resistance in said patient is not significantly raised following administration of said α 1A -AR partial agonist. 
     
     
         4 . The method of  claim 1 , wherein the supine systolic blood pressure in said patient does not rise more than about 25% as compared to the patient's blood pressure prior to administration of the α 1A -AR partial agonist. 
     
     
         5 . The method of  claim 1 , wherein said nOH in said patient is associated with one or more of Parkinson's disease, multiple system atrophy, and pure autonomic failure. 
     
     
         6 . The method of  claim 5 , wherein said nOH in said patient is associated with Parkinson's disease. 
     
     
         7 . The method of  claim 1 , wherein said patient takes a dose of the α 1A -AR partial agonist once daily. 
     
     
         8 . The method of  claim 1 , wherein said patient takes a dose of the α 1A -AR partial agonist twice daily. 
     
     
         9 . The method of  claim 1 , wherein said patient takes a dose of the α 1A -AR partial agonist three times daily. 
     
     
         10 . The method of  claim 1 , wherein said patient takes a dose of the α 1A -AR partial agonist four times daily. 
     
     
         11 . The method of  claim 1 , wherein said patient takes a first daily dose of said α 1A -AR partial agonist immediately after the patient wakes in the morning.